Axonics (STU:0I3) Total Stockholders Equity : €576.9 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Axonics Total Stockholders Equity?

Axonics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €576.9 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Axonics's Book Value per Share for the quarter that ended in Mar. 2024 was €11.31. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Axonics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.05.

Axonics Total Stockholders Equity Historical Data

The historical data trend for Axonics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Total Stockholders Equity Chart

Axonics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

164.70

236.22

426.96

538.21

584.65

Axonics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															538.55	554.29	572.15	584.65	576.93

Axonics (STU:0I3) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Axonics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(576.931	-	0)	/	51.0182
	=	11.31

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Axonics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.34	+	27.742)	/	576.931
	=	0.05

Axonics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Axonics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Axonics (STU:0I3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (STU:0I3) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

AXNX:USA 0I3:Germany

Address

26 Technology Drive, Irvine, CA, USA, 92618

Website

https://www.axonics.com

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.

Axonics (STU:0I3) Headlines

No Headlines